How to Live a Healthy Life with HIV?

Living a long and healthy life with HIV is achievable with the right approach to treatment, lifestyle choices, and ongoing medical support. Every person’s journey with HIV is unique, so whether you are newly diagnosed or have been living with HIV for years, staying in regular contact with your healthcare provider or an HIV specialist is essential.

Find the Right HIV Treatment for You

HIV treatment plays a crucial role in maintaining overall health and preventing transmission. Antiretroviral therapy (ART) can help you achieve undetectable viral levels, a well-established scientific principle known as U=U (Undetectable = Untransmittable). When your viral load is undetectable, HIV cannot be transmitted to sexual partners, making treatment a powerful tool in both personal health and HIV prevention.

However, HIV treatment is not one-size-fits-all. Each person responds differently to medications, and some treatments may cause side effects. Regular consultations with an HIV healthcare provider ensure that you are on the best possible regimen suited to your individual needs. Open communication with your doctor will help you understand the benefits and side effects of different HIV treatment options, ensuring long-term viral suppression and improved well-being.

Healthy Lifestyle Choices for People Living with HIV

Maintaining a healthy lifestyle is essential for supporting your immune system and overall well-being. Here are key steps you can take to optimize your health while living with HIV:

1. Exercise Regularly

Physical activity strengthens the immune system, improves heart health, and boosts mental well-being. Engaging in moderate exercise like walking, yoga, or strength training can help maintain a healthy weight and reduce stress.

2. Eat a Balanced Diet

A nutrient-rich diet supports immune function and overall health. Focus on whole foods, including:
– Fruits and vegetables for essential vitamins and antioxidants
– Lean proteins (chicken, fish, tofu) to support muscle and immune function
– Whole grains for sustained energy
– Healthy fats (avocados, nuts, olive oil) for heart and brain health

3. Avoid Smoking and Limit Alcohol

Smoking weakens the immune system and increases the risk of infections, cancers, and cardiovascular disease. If you smoke, consider quitting smoking programs. Similarly, excessive alcohol consumption can interfere with medications and weaken liver function. Drink in moderation or seek support if needed.

4. Manage Stress and Get Enough Sleep

Chronic stress can weaken the immune system and impact overall health. Practice stress management techniques such as meditation, deep breathing, or counseling. Additionally, getting 7-9 hours of sleep per night is vital for immune function and mental clarity.

5. Avoid Recreational Drugs

Drug use can interfere with HIV medication effectiveness and weaken the immune system. Seek support from healthcare professionals if you need help managing substance use.

Personal Stories: Living a Long Life with HIV

Many individuals have thrived for decades while living with HIV. George, a person living with HIV in his 90s, credits his longevity to staying on the most appropriate HIV treatment plan, maintaining a healthy lifestyle, and having strong support from his husband, Somchai.

Like several people under the treatment in Naval AIDS Research Center, you can live a fulfilling and long life with HIV by:
– Staying informed about the latest HIV treatment options
– Communicating regularly with your healthcare provider
– Making choices that support immune health and overall wellness

Conclusion

HIV is a manageable condition, and with the right treatment and lifestyle adjustments, you can lead a healthy, active, and long life. Regular medical care, adherence to HIV treatment, and maintaining a balanced lifestyle are key to thriving with HIV. Stay proactive, informed, and connected to your healthcare team for the best possible health outcomes.

How Does HIV Affect Your Life?

While people living with HIV can lead long and fulfilling lives, they may still face daily challenges. The impact of HIV varies from person to person, but here are some key ways it can affect daily life:

1. Lifelong HIV Treatment

Antiretroviral therapy (ART) is essential for managing HIV viral load and preventing disease progression. However, adherence to medication is crucial, as missing doses can lead to drug resistance.

2. Managing Treatment Side Effects

Some HIV medications can cause side effects such as nausea, fatigue, or dizziness. While many side effects are temporary, others may require adjustments to treatment. Regular check-ins with a healthcare provider can help manage these issues effectively.

3. Blood and Organ Donation Restrictions

In most countries, people living with HIV are not eligible to donate blood or organs. However, in rare cases, HIV-positive organ transplants have been used to save the lives of people also living with HIV.

4. Emotional Well-Being and Mental Health

Many individuals experience anxiety, depression, or loneliness after diagnosis. Seeking HIV support groups, therapy, or counseling can help improve emotional resilience and mental well-being.

5. HIV Stigma and Discrimination

Unfortunately, HIV stigma remains a challenge. Some people may experience discrimination in workplaces, relationships, and healthcare settings. Education and awareness play a key role in reducing stigma and empowering those affected.

Despite these challenges, a strong support system can help individuals overcome obstacles and thrive while living with HIV.

How to Overcome Challenges and Live Confidently with HIV

Helen, originally from Uganda and now living in Amsterdam, shares her experience of living with HIV and how she refuses to let it define her. Watch her inspiring story to learn how she navigates life with confidence.

Getting Support After an HIV Diagnosis

People living with HIV have access to a variety of support services for social, emotional, and financial needs. Many HIV support organizations provide counseling, healthcare navigation, and community resources.

Thanks to telehealth and online resources, people can now receive HIV care and support remotely, making it easier to stay informed and connected.

Here are some valuable HIV support resources:
Naval AIDS Research Center in India provides all kinds of of treatment to the HIV patients

• AVERT – A UK-based charity offering trusted information on HIV prevention, treatment, and sexual health.
• BeyondPositive – Provides advice on mental health, lifestyle, and treatment, along with personal HIV community stories.
• HIV I-Base – A medical resource offering HIV treatment guides and Q&A services, developed with input from people living with HIV.
•  HIV.gov – A US-based platform featuring HIV news, prevention strategies, and informational resources.

Sharing Your HIV Status: What You Need to Know

Deciding whether to share your HIV-positive status is a personal choice. While it can be a big decision, support is available to help navigate these conversations.

1. Telling Friends and Family

Disclosing your status to loved ones can be emotionally challenging, but it can also provide emotional support and strengthen relationships. Choose a trusted person who will support and respect your journey.

2. HIV Disclosure at Work

Depending on your country’s laws, you may or may not be required to disclose your HIV status to an employer. Research suggests that many people fear workplace discrimination, but actual cases of job loss due to HIV disclosure are less common than anticipated. Understanding your rights and workplace policies can help you make an informed decision.

If you experience HIV-related workplace discrimination, seek legal advice or consult HIV advocacy organizations for support.

Living a Fulfilling Life with HIV: Moritz’s Journey

Moritz Krehl was diagnosed with HIV in 2011. By maintaining open communication with his doctors and adopting a holistic approach to treatment, he has found a way to live confidently. Watch his story to learn more about thriving with HIV.

Conclusion

HIV may present challenges, but it does not define your life. By staying informed, receiving proper medical care, and surrounding yourself with a supportive community, you can lead a healthy, active, and fulfilling life.

HIV Treatment and Preventing Transmission

For individuals living with HIV, taking the right antiretroviral therapy (ART) is crucial for maintaining health and preventing transmission. Since HIV treatment is not one-size-fits-all, it’s important to discuss evolving treatment options with your doctor to find the best fit for your needs.

How Does HIV Treatment Work?

HIV treatment helps reduce the viral load in the body, sometimes to undetectable levels. When the virus is undetectable, it cannot be transmitted to sexual partners—this is known as U=U (Undetectable = Untransmittable). Achieving an undetectable viral load is one of the most effective ways to stay healthy and prevent HIV transmission.

Pregnancy and HIV

People living with HIV can have healthy pregnancies with the right medical care. By maintaining an undetectable viral load, the risk of passing HIV to the baby is significantly reduced.

Managing HIV During Pregnancy

• ART During Pregnancy: Continuing antiretroviral treatment is essential for both the mother’s health and reducing the risk of transmission.
• Delivery Options: In some cases, doctors may recommend a cesarean section (C-section) to further lower transmission risk.
• Breastfeeding Considerations: Since HIV can be transmitted through breast milk, formula feeding is often advised.

While HIV and pregnancy research is ongoing, it is important to discuss risks, benefits, and ART treatment safety with your healthcare provider.

Living with HIV and Other Health Conditions

People living with HIV can develop the same age-related health conditions as the general population, such as heart disease, kidney disease, and diabetes. However,

HIV can also increase the risk of:

• Hepatitis B and C infections
• Certain types of cancer
• Chronic inflammation-related conditions

Managing HIV and Comorbidities

When someone has HIV and another chronic condition, this is called a comorbidity. Studies suggest that 29% of people with HIV have at least one common comorbidity. Managing multiple health conditions requires a personalized HIV treatment plan that considers both HIV and other underlying illnesses.

Opportunistic Infections and HIV

Opportunistic infections (OIs) occur more frequently in people with weakened immune systems, especially when CD4 cell counts drop below 250. However, taking effective HIV treatment significantly reduces this risk.

Common Opportunistic Infections (OIs) in HIV

• Bacterial infections: Tuberculosis (TB), bacterial pneumonia
• Fungal infections: Thrush, pneumocystis pneumonia
• Parasitic infections: Toxoplasmosis
• Viral infections: Herpes simplex virus

If you are at risk for opportunistic infections, your doctor may recommend preventive treatments to lower the chances of developing severe illness.

Traveling with HIV

Most countries allow people living with HIV to travel freely. However, some nations have restrictions for long-term stays or permanent residency.

Tips for Traveling with HIV

Research the entry policies of your destination country.
Carry an adequate supply of HIV medication and a doctor’s note if necessary.
Plan ahead for medical care access while abroad.

If you are unsure about HIV travel regulations, check with your local embassy or HIV advocacy organizations before planning your trip.

Resources for People Living with HIV

Everyone’s HIV journey is unique, and various resources are available to provide guidance, support, and education.

HIV in Women

Learn about HIV prevalence in women, global statistics, female-to-male HIV transmission, and women’s health concerns related to HIV and pregnancy.

Starting Your HIV Journey

If you’ve recently been diagnosed, this section helps you understand HIV basics, learn about U=U (Undetectable = Untransmittable), and find support for navigating life with HIV treatment and care.

Choosing the Right HIV Treatment

Explore treatment options and find the best HIV medication for your lifestyle. Understanding side effects, new treatment developments, and ART options can help you feel in control of your care.

Living a Healthy Life with HIV

Maintaining physical, mental, and emotional health is key to long-term well-being. Discover tips on mental health, aging with HIV, and planning for the future.

Talking to Your Doctor

A strong relationship with your HIV healthcare team is essential. Learn how to prepare for medical appointments, discuss treatment changes, and advocate for your health confidently.

Conclusion

HIV is a manageable condition, and with the right treatment, support, and lifestyle choices, you can live a healthy and fulfilling life. Whether managing HIV treatment, pregnancy, travel, or other health conditions, staying informed and proactive ensures long-term wellness.

References:

1. Life expectancy for people living with HIV. 2023. Available at: https://www.aidsmap.com/about-hiv/life-expectancy-people-living-hiv [Accessed: August 2024]
2. National Health Service. Treatment – HIV and AIDS. 2024. Available at: https://www.nhs.uk/conditions/hiv-and-aids/treatment/ [Accessed: August 2024.
3. Centers for Disease Control and Prevention. Living with HIV. 2024. Available at: https://www.cdc.gov/hiv/living-with/index.html [Accessed: August 2024]
4. gov. Exercise and Physical Activity. 2022. Available at: https://www.hiv.gov/hiv-basics/living-well-with-hiv/taking-care-of-yourself/exercise-and-physical-activity [Accessed: August 2024]
5. National Institutes of Health. HIV and Nutrition and Food Safety. 2021. Available at: https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-nutrition-and-food-safety
   [Accessed: August 2024]
6. Centers for Disease Control and Prevention. Smoking and HIV. 2023. Available at: https://www.cdc.gov/tobacco/campaign/tips/diseases/smoking-and-hiv.html#
   [Accessed: August 2024]
7. National Health Service. Living with – HIV and AIDS. 2024. Available at: https://www.nhs.uk/conditions/hiv-and-aids/living-with/ [Accessed: August 2024]
8. National AIDS Trust. Why we need HIV support services. 2017. Available at: https://www.nat.org.uk/sites/default/files/publications/NAT_WHY%20WE%20NEED%20HIV%20SUPPORT%20SERVICES_2017_56%20pages_FINAL%20WEB_SINGLE%20PAGE….pdf [Accessed: July 2024]
9. Living beyond HIV: Taking a Positive Perspective
10. National Institutes of Health.10 Things to Know About HIV Suppression.2024. Available at: https://www.niaid.nih.gov/diseases-conditions/10-things-know-about-hiv-suppression [Accessed: August 2024]
11. Irshad U, Heba Mahdy, Tonismae T. HIV in Pregnancy. Nih.gov. 2023. Available at: https://www.ncbi.nlm.nih.gov/books/NBK558972/ [Accessed: August 2024]
12. Royal College of Obstetrics and Gynaecologists (RCOG). HIV and pregnancy.2019. Available at: https://www.rcog.org.uk/for-the-public/browse-our-patient-information/hiv-and-pregnancy/[Accessed: August 2024]
13. End-liver disease is a concern for people with HIV and hepatitis B or C co-infection. 2015. Available at: https://www.aidsmap.com/news/apr-2015/end-stage-liver-disease-concern-people-hiv-and-hepatitis-b-or-c-co-infection [Accessed: August 2024]
14. Lorenc A, et al. The prevalence of comorbidities among people living with HIV in Brent: a diverse London Borough. London J Prim Care (Abingdon). 2014;6(4):84-90.
15. Althoff KN, Smit M, Reiss P, Justice AC. HIV and ageing: improving quantity and quality of life. Current Opinion in HIV and AIDS. 2016 Sep 1;11(5):527-36.
16. Burki T. People ageing with HIV face an uncertain future. The Lancet HIV. 2019;6(12):e816-e817.
17. gov. Opportunistic Infections Available at: https://www.hiv.gov/hiv-basics/staying-in-hiv-care/other-related-health-issues/opportunistic-infections [Accessed August 2024]
18. Still not welcome: HIV-related travel restrictions. 2019. Available at: https://www.unaids.org/sites/default/files/media_asset/hiv-related-travel-restrictions-explainer_en.pdf [Accessed August 2024
19. org. UNAIDS and UNDP call on 48 countries and territories to remove all HIV-related travel restrictions. (2021). Available at: https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2019/june/20190627_hiv-related-travel-restrictions [Accessed August 2024]
20. uk (no date) Who can become an organ donor?, NHS choices. Available at: https://www.organdonation.nhs.uk/helping-you-to-decide/about-organ-donation/who-can-donate/ (Accessed: 23 October 2024).

HIV FAQs: Understanding the Virus, Prevention, and Treatment

This page addresses common questions about HIV, including the difference between HIV and AIDS, various HIV prevention methods, and the latest advancements toward finding a cure for HIV.

For additional information, you can visit the National Institutes of Health (NIH) website for a comprehensive overview of HIV symptoms, transmission, and treatment. You can also explore our in-depth guides on:

• HIV prevention and testing
• HIV treatment options
• The power of U=U (Undetectable = Untransmittable)

Frequently Asked Questions (FAQs) About HIV

• What’s the difference between HIV and AIDS?
• Why are people living with HIV excluded from some clinical trials?
• Can people living with HIV donate blood?
• How close are scientists to finding a cure for HIV?
• Does HIV cause accelerated aging?
• Who is more affected by HIV, men or women?
• What are the chances of female-to-male HIV transmission?
• What is PrEP and PEP in HIV prevention?
• What are the drug interactions of HIV medications?

What’s the Difference Between HIV and AIDS?

HIV (Human Immunodeficiency Virus) is a virus that attacks the immune system, whereas AIDS (Acquired Immunodeficiency Syndrome) is a condition that can develop in people with untreated or advanced HIV.

Not all individuals with HIV will develop AIDS, thanks to antiretroviral therapy (ART), which effectively suppresses the virus and prevents progression to AIDS. With consistent HIV treatment, people with HIV can live long, healthy lives and reduce their viral load to an undetectable level, making HIV untransmittable (U=U).

Early HIV diagnosis and treatment are crucial to maintaining health and preventing transmission.

You May Also Be Interested In:

The Power of U=U (Undetectable = Untransmittable) in HIV

Learn how achieving an undetectable viral load eliminates the risk of transmission and helps reduce HIV stigma while promoting sex positivity and awareness.

Finding a Cure for HIV: Our Research and Progress

Ending the HIV epidemic requires both effective treatments and a cure. Explore ongoing HIV cure research, including gene therapy, monoclonal antibodies, and immune system modulation.

HIV in Women: Understanding Risks and Prevention

Discover global HIV statistics in women, learn about female-to-male HIV transmission, and explore HIV-related health concerns specific to women.

Common HIV-Related Terms & Abbreviations

• HIV – Human Immunodeficiency Virus
• AIDS – Acquired Immunodeficiency Syndrome
• ART – Antiretroviral Therapy (HIV treatment)
• U=U – Undetectable = Untransmittable (no risk of HIV transmission when viral load is undetectable)
• PrEP – Pre-Exposure Prophylaxis (medication to prevent HIV)
• PEP – Post-Exposure Prophylaxis (emergency medication after potential exposure to HIV)
• oPEP – Occupational PEP (for workplace HIV exposure)
• nPEP – Non-Occupational PEP (for personal HIV exposure)

Conclusion

Understanding the difference between HIV and AIDS, the effectiveness of ART treatment, and the importance of early diagnosis can help people living with HIV lead healthy, fulfilling lives. With scientific advancements, prevention strategies like PrEP and PEP, and ongoing HIV cure research, the fight against HIV continues to move forward.

References:

1. HIV and AIDS: The Basics. Understanding HIV fact sheet. Nih.Gov. Retrieved 20 December 2023, from https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-aids-basics
2. HIV/AIDS Glossary. Antiretroviral therapy (ART). Clinical Info HIV.Gov. Retrieved 20 December 2023, from https://clinicalinfo.hiv.gov/en/glossary/antiretroviral-therapy-art
3. HIV and AIDS Clinical Trials. (n.d.). Nih.Gov. Retrieved 20 December 2023, from https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-aids-clinical-trials
4. Diversity and Inclusion in Clinical Trials. NIMHD. Published 2021. Accessed December 20, 2023. https://www.nimhd.nih.gov/resources/understanding-health-disparities/diversity-and-inclusion-in-clinical-trials.html
5. Guidelines Regarding the Inclusion of Cancer Survivors and HIV-Positive Individuals on Clinical Trials. https://ctep.cancer.gov/protocoldevelopment/policies_hiv.htm#:~:text=Such%20grounds%20for%20exclusion%20may,or%20response%20to%20the%20treatment.
6. Venturelli S, Dalla Pria A, Stegmann K, Smith P, Bower M. The exclusion of people living with HIV (PLWH) from clinical trials in lymphoma. Br J Cancer. 2015;113(6):861-863. doi:10.1038/bjc.2015.301
7. Blood Donor Counselling: Implementation Guidelines. Geneva: World Health Organization; 2014. Annex 5, HIV infection: information for blood donors. Available from: https://www.ncbi.nlm.nih.gov/books/NBK310571/
8. NHS blood and transplant. Who can give blood? Retrieved 20 December 2023, from https://www.blood.co.uk/who-can-give-blood/
9. Bonney EY, Lamptey H, Kyei GB. HIV cure: an acceptability scientific agenda. Curr Opin HIV AIDS. 2023;18(1):12-17. doi:10.1097/COH.0000000000000771
10. Akusjärvi SS, Neogi U. Biological Aging in People Living with HIV on Successful Antiretroviral Therapy: Do They Age Faster?. Curr HIV/AIDS Rep. 2023;20(2):42-50. doi:10.1007/s11904-023-00646-0
11. Rodés B, Cadiñanos J, Esteban-Cantos A, Rodríguez-Centeno J, Arribas JR. Ageing with HIV: Challenges and biomarkers. EBioMedicine. 2022;77:103896. doi:10.1016/j.ebiom.2022.103896
12. Chawla A, Wang C, Patton C, et al. A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population. Infect Dis Ther. 2018;7(2):183-195. doi:10.1007/s40121-018-0201-6
13. Girum T, Wasie A, Lentiro K, et al. Gender disparity in epidemiological trend of HIV/AIDS infection and treatment in Ethiopia. Arch Public Health. 2018;76:51. Published 2018 Sep 17. doi:10.1186/s13690-018-0299-8
14. Global HIV & AIDS statistics. Geneva:UNAIDS Data; 2022.
15. gov . How Does HIV Impact Women’s Health? HIV.gov. Published 2022. Accessed December 20, 2023. https://www.hiv.gov/hiv-basics/staying-in-hiv-care/other-related-health-issues/womens-health-issues/
16. Kushnir VA, Lewis W. Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals. Fertil Steril. 2011;96(3):546-553. doi:10.1016/j.fertnstert.2011.05.094
17. Wall KM, Stephenson R, Sullivan PS. Frequency of sexual activity with most recent male partner among young, Internet-using men who have sex with men in the United States. J Homosex. 2013;60(10):1520-1538. doi:10.1080/00918369.2013.819256
18. Boily MC, Baggaley RF, Wang L, et al. Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis. 2009;9(2):118-129. doi:10.1016/S1473-3099(09)70021-0
19. Shaw GM, Hunter E. HIV transmission. Cold Spring Harb Perspect Med. 2012;2(11):a006965. Published 2012 Nov 1. doi:10.1101/cshperspect.a006965
20. Territo H, Vaqar S, Justiz Vaillant AA. HIV Prophylaxis. [Updated 2023 May 8]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK534852/
21. Stolbach A, Paziana K, Heverling H, Pham P. A Review of the Toxicity of HIV Medications II: Interactions with Drugs and Complementary and Alternative Medicine Products. J Med Toxicol. 2015;11(3):326-341. doi:10.1007/s13181-015-0465-0
22. Kaur K, Gandhi MA, Slish J. Drug-Drug Interactions Among Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Medications. Infect Dis Ther. 2015;4(2):159-172. doi:10.1007/s40121-015-0061-2 NP-GBL-HVX-COCO-240002 February 2025

HIV Clinical Trials, Blood Donation, and Advances in HIV Cure Research

Why Are People Living with HIV Excluded from Certain Clinical Trials?

People living with HIV are not excluded from HIV clinical trials. In fact, participation in these trials is essential for developing new and improved HIV treatments. Every FDA-approved HIV treatment available today has undergone rigorous clinical trials to ensure its safety and efficacy.

The Importance of Diversity in HIV Research

Inclusion of people from diverse backgrounds in clinical trials is crucial. Factors like genetics, metabolism, and immune response can influence how individuals react to medications. By ensuring diverse participation, researchers can:

– Improve treatment effectiveness for all populations.

– Develop safer HIV therapies with fewer side effects.

– Provide equal healthcare access to marginalized communities.

Why Are People with HIV Excluded from Some Non-HIV Clinical Trials?

Despite progress in inclusion, some clinical trials outside HIV research still exclude people living with HIV. This is due to:

– Compromised immune systems, which may impact drug responses.

– Co-infections such as hepatitis B or tuberculosis.

– Drug interactions between HIV medications and experimental treatments.

– Immunomodulatory drug trials, where altered immune responses may skew results.

However, recent years have seen a shift toward greater inclusion of HIV-positive individuals in non-HIV trials. Many organizations now prioritize diverse participation, ensuring that research reflects real-world populations.

Can People Living with HIV Donate Blood?

Currently, people living with HIV cannot donate blood, regardless of their viral load. This policy exists because HIV can be transmitted through blood transfusions. While antiretroviral therapy (ART) effectively suppresses HIV, blood donation remains restricted to minimize risk.

Since blood donation regulations differ by country, it is advisable to check with local blood transfusion authorities for the latest guidelines.

How Close Are Scientists to Finding a Cure for HIV?

While ART has transformed HIV into a manageable condition, it does not completely eliminate the virus. Scientists continue researching HIV cure strategies, including:

1. The ‘Shock and Kill’ Approach

– Uses small molecules to reactivate dormant HIV in the body.

– Once exposed, the immune system or targeted therapies can eliminate infected cells.

2. The ‘Block and Lock’ Approach

– Puts the virus into deep latency, preventing it from reactivating even if ART is stopped.

– Research is ongoing to determine if this could lead to a functional cure.

3. Immunotherapy and Monoclonal Antibodies

– Enhances the immune system to target and destroy HIV-infected cells.

– Could help prevent HIV rebound when ART is discontinued.

4. Gene Editing and CRISPR-Based Therapies

– Aims to remove HIV DNA from infected cells.

– Still in early research stages but shows promising potential.

Despite significant progress, achieving a complete HIV cure remains a complex challenge.

Does HIV Cause Faster Aging?

HIV does not directly cause premature aging, but chronic inflammation and long-term ART use may contribute to age-related conditions. People living with HIV are at a higher risk of:

– Cardiovascular diseases

– Osteoporosis and bone density loss

– Cognitive decline and dementia

– Diabetes and metabolic disorders

Managing Aging with HIV

To maintain long-term health, individuals living with HIV should:

– Adhere to HIV treatment to maintain an undetectable viral load.

– Follow a balanced diet and exercise regularly.

– Monitor for age-related health conditions and manage medications effectively.

– Work closely with healthcare providers to optimize overall health.

Understanding the Challenges of Aging with HIV

Personal Story: Paul’s Journey with HIV

Paul was diagnosed with HIV in 1988, during a time of high stigma and misinformation. Today, as a long-term survivor, he highlights the importance of:

– Advocating for personalized HIV care.

– Managing multiple medications for co-existing health conditions.

– Addressing both HIV-related and age-related health concerns.

Healthcare providers must take a holistic approach to HIV treatment, considering the long-term impact of ART and interactions with other medications.

The Growing Aging Population with HIV

Research shows a dramatic increase in the aging HIV population. A study in The Lancet HIV predicts:

– The median age of people with HIV in the Netherlands will rise from 44 years in 2010 to 57 years by 2030.

– The proportion of people aged 50 or older with HIV will increase from 28% in 2010 to 73% in 2030.

As people live longer with HIV, there is a growing need for:

– Specialized research on aging and HIV.

– Improved treatment plans to minimize drug interactions.

– Support systems addressing mental health and social stigma.

Future of HIV Treatment for Older Adults

Modern antiretroviral therapies (ARTs) allow many individuals with HIV to achieve a near-normal lifespan. However, aging brings additional health risks that require attention, including:

– Heart disease and hypertension.

– Liver and kidney complications.

– Cancers linked to chronic inflammation.

The future of HIV treatment focuses on developing medications with fewer side effects, better safety profiles, and limited toxicity to vital organs.

Reducing the Long-Term Burden of HIV Treatment

Scientists are researching how to:

– Minimize the impact of ART on aging populations.

– Enhance treatment safety while maintaining viral suppression.

– Develop therapies that require fewer medications for people managing multiple conditions.

Addressing HIV Stigma

While HIV treatment has advanced significantly, social stigma remains a major challenge. In some countries, misinformation and discrimination persist, making it harder for individuals to access care.

Fighting HIV Stigma Through Awareness

– Educating communities on the effectiveness of ART and U=U.

– Advocating for equal access to healthcare for aging HIV populations.

– Challenging outdated policies that restrict employment and travel for people with HIV.

Mapping the Future of HIV Care

The future of HIV care focuses on innovative treatments, long-term health management, and reducing stigma. ViiV Healthcare and other global organizations are committed to:

– Conducting specialized research on HIV and aging.

– Improving quality of life through patient-centered care.

– Developing better HIV treatment options with fewer side effects.

As research continues, the goal remains clear: to improve the lives of people living with HIV and ultimately find a cure.

References

• 
  McGettigan, P., Morales, D.R., Moreno‐Martos, D. and Matin, N. (2022). Changing co‐morbidity and increasing deprivation among people living with HIV: UK population‐based cross‐sectional study. HIV Medicine. doi:https://doi.org/10.1111/hiv.13389.
• 
  Smit et al., Lancet Infect Dis 2015 Jul;15(7):810-8). Global AIDS Update. Available at: https://aids2020.unaids.org/report/. Accessed August 2020
• 
  AIDS info. Available at: http://aidsinfo.unaids.org/. Accessed August 2020
• 
  The Gap Report. Available at: http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf. Last accessed: Nov 2016
• 
  Smit M, Brinkman K, Geerlings S, et al. Future challenges for clinical care of an ageing population infected with HIV: a modelling study. Lancet Inf Dis 2015;15:810-18.
• 
  Gebo KA. Epidemiology of HIV and response to antiretroviral therapy in the middle aged and elderly. Aging Health 2008; 4: 615–27
• 
  Okoli C, de los Rios P, Eremin A, Brough G, Young B, Short D. Relationship Between Polypharmacy and Quality of Life Among People in 24 Countries Living With HIV. Prev Chronic Dis 2020;17:190359. DOI: http://dx.doi.org/10.5888/pcd17.190359
• 
  Nobili A. Multiple diseases and polypharmacy in the elderly: challenges for the internist of the third millennium. J Comorbidity 2011; 1:28–44

HIV Transmission, Prevention, and Drug Interactions

Who Is More Affected by HIV: Males or Females?

HIV affects both males and females, but the impact varies depending on region, socio-economic conditions, and healthcare access. Globally, the distribution of HIV cases is relatively balanced. However, in certain areas, one gender may be disproportionately affected. For example, in Ethiopia, women account for 60% of all HIV infections.

HIV and Women’s Health

Women living with HIV may experience unique health challenges, including:

– Gynecological health issues, such as chronic infections.

– Higher risk of cervical cancer due to HPV co-infection.

– Increased risk of heart disease and infertility.

Social and Economic Factors

HIV prevalence can be influenced by factors such as:

– Limited access to healthcare.

– Gender-based violence and discrimination.

– Cultural barriers preventing HIV education and prevention.

To learn more about HIV in women, visit our dedicated resource page.

What Are the Chances of HIV Transmission from Female to Male?

The risk of female-to-male HIV transmission is generally lower than male-to-female transmission. Studies show that:

– In high-income countries, the estimated transmission rate from female to male is 0.04% per act, whereas male-to-female transmission is 0.08%.

– In low-income countries, both rates are higher: 0.38% for male-to-female transmission and 0.3% for female-to-male.

Factors Influencing HIV Transmission Risk

Several factors impact the likelihood of transmission:

– Viral Load: Higher viral loads increase transmission risk, while an undetectable viral load (U=U) means HIV cannot be transmitted.

– Stage of Infection: The risk is highest during the acute phase of infection when the virus replicates rapidly.

– Condom Use: Consistent and correct condom use significantly reduces HIV transmission risk.

– PrEP (Pre-Exposure Prophylaxis): PrEP is a medication that can prevent HIV infection when taken correctly.

What Is PrEP and PEP in HIV Prevention?

HIV prevention strategies include:

– Pre-Exposure Prophylaxis (PrEP): A daily medication that reduces the risk of HIV infection in HIV-negative individuals.

– Post-Exposure Prophylaxis (PEP): Emergency medication taken within 72 hours after potential HIV exposure to prevent infection.

– Occupational PEP (oPEP): Used by individuals exposed to HIV at work, such as healthcare professionals.

– Non-Occupational PEP (nPEP): Used after potential exposure from sexual activity or intravenous drug use.

What Are the Drug Interactions of HIV Medications?

HIV medications may interact with other drugs, affecting their effectiveness and side effects. Common drug interactions include:

– Anticoagulants (e.g., warfarin) – May require dosage adjustments.

– Hormonal contraceptives – Some HIV medications can reduce contraceptive effectiveness.

– Antimalarial drugs – Certain ARTs can alter drug metabolism.

– Cholesterol and blood pressure medications – Require monitoring to avoid adverse effects.

– Recreational drugs and herbal supplements (e.g., St. John’s Wort) – Can interfere with HIV treatment efficacy.

HIV Prevention: Everything You Should Know

HIV prevention strategies include both medical and non-medical approaches:

Non-Medical HIV Prevention Methods:

– Condom use and safe sex practices.

– Education and communication about HIV risks.

– Regular HIV testing and partner disclosure.

Medical HIV Prevention Methods:

– PrEP (Pre-Exposure Prophylaxis) and PEP (Post-Exposure Prophylaxis).

– Treatment as Prevention (TasP): ART reduces viral load, preventing transmission.

– Harm reduction strategies: Needle exchange programs and safer drug use practices.

Everyone should have access to multiple HIV prevention options. Consult your doctor or sexual health practitioner to determine the best approach for your lifestyle and needs.

How Is HIV Transmitted?

HIV can only be transmitted through direct contact with certain bodily fluids from a person with a detectable viral load. These fluids include:

– Semen and vaginal fluids.

– Rectal fluids.

– Blood.

– Breast milk.

Main Modes of HIV Transmission:

– Sexual transmission (vaginal or anal sex without protection).

– Intravenous drug use (sharing needles or syringes).

– Mother-to-child transmission during pregnancy, childbirth, or breastfeeding.

Oral Sex and HIV Risk

The risk of HIV transmission through oral sex is very low, estimated between 0% and 0.04% per act. Factors that may slightly increase risk include:

– Ejaculation in the mouth.

– Presence of open sores or bleeding gums.

– Co-existing sexually transmitted infections (STIs).

Conclusion

Understanding HIV transmission, prevention, and treatment is crucial for reducing infections worldwide. Whether through PrEP, PEP, TasP, or safer sex practices, there are multiple ways to protect yourself and others. Staying informed and consulting healthcare professionals can help determine the best prevention and treatment strategies tailored to your individual needs.

Effective Ways to Prevent HIV Transmission

Pre-Exposure Prevention Strategies

Preventing HIV transmission begins with proactive measures before exposure. These include:

1. Using Condoms

How effective are condoms in preventing HIV?

– Condoms are highly effective in reducing the risk of HIV and other STIs, but they are not 100% foolproof, as they can break during sexual intercourse.

– Both external condoms (male condoms) and internal condoms (female condoms) provide a barrier method that significantly lowers HIV transmission risk.

– Internal condoms offer added protection by covering more skin areas where STIs can spread.

2. Reducing Risky Behaviors

HIV exposure risk increases with certain behaviors, such as:

– Engaging in condomless anal or vaginal sex without knowing your partner’s HIV status.

– Having multiple anonymous sexual partners, limiting discussions about HIV prevention.

– Substance use during sex (chemsex), as alcohol and drugs lower inhibitions and increase risk-taking behaviors.

3. HIV Prevention for Serodiscordant Couples

A serodiscordant couple is where one partner is HIV-positive and the other is HIV-negative. In such relationships:

– HIV-positive individuals should take antiretroviral therapy (ART) consistently to achieve an undetectable viral load (U=U), which means they cannot transmit HIV.

– HIV-negative partners can use Pre-Exposure Prophylaxis (PrEP) for additional protection.

– Regular viral load monitoring ensures that ART remains effective in maintaining undetectable levels.

Importance of HIV and STI Testing

Knowing Your HIV Status

– Regular HIV testing allows for early diagnosis and timely treatment, reducing transmission risks.

– Open conversations about HIV status help normalize testing and encourage safer sex practices.

STI Testing and HIV Risk

– STIs such as chlamydia, gonorrhea, and syphilis increase HIV risk by causing sores or breaks in the skin that make transmission easier.

– Regular STI screening is essential for anyone who is sexually active.

To find local HIV and STI testing services, visit healthcare providers or HIV awareness organizations.

Pre-Exposure Prophylaxis (PrEP)

PrEP is one of the most effective HIV prevention tools, offering up to 99% protection when taken correctly.

Who Should Consider PrEP?

PrEP is recommended for individuals who:

– Have a sexual partner living with HIV, especially if their viral load status is unknown.

– Engage in condomless sex or have been diagnosed with STIs in the past six months.

– Share needles, syringes, or drug equipment with others.

– Have multiple sexual partners or high-risk exposures.

– Have been prescribed Post-Exposure Prophylaxis (PEP) multiple times.

Types of PrEP Available

1. Daily Oral PrEP – A pill taken once daily for continuous HIV prevention.
2. Long-Acting Injectable (LAI) PrEP – Administered monthly but not yet available in all countries.

Post-Exposure Prophylaxis (PEP)

PEP is an emergency HIV prevention treatment taken after potential exposure to HIV.

Key Facts About PEP

– PEP must be started within 72 hours after exposure to be effective.

– A 28-day treatment course must be completed daily.

– PEP is intended for emergency use, not as a regular prevention method.

– If you are frequently exposed to HIV, consider PrEP as a better long-term option.

Common Questions About HIV Prevention

1. How can perinatal HIV transmission be prevented?

Perinatal transmission occurs when a pregnant person living with HIV passes the virus to their baby. Prevention includes:

– Taking ART during pregnancy to lower transmission risk to less than 1%.

– Providing preventive medicine to newborns.

– Using formula or pasteurized donor human milk if the parent has a detectable viral load.

2. Can lubricants prevent HIV?

– Lubricants do not directly prevent HIV, but they reduce friction and lower the chance of condom breakage.

– Water-based and silicone-based lubricants are recommended for safer sex.

3. Is there an HIV prevention vaccine?

– Currently, no HIV vaccine exists, but research is ongoing.

– Past trials, such as Mosaico (2019), were unsuccessful, but new vaccine developments continue.

4. Can circumcision reduce HIV risk?

– Circumcision lowers the risk of HIV infection by 50-60% in heterosexual men, but it is not a standalone prevention method.

– Condom use and PrEP offer greater protection against HIV.

5. Is PEP stronger than PrEP?

– PEP and PrEP serve different purposes:

  – PEP is taken after HIV exposure for 28 days.

  – PrEP is taken before exposure for ongoing protection.

– PEP contains three drugs, while PrEP contains two.

6. Can antibiotics prevent HIV?

– No, antibiotics do not prevent HIV, as HIV is a virus, not a bacterial infection.

– PEP is the correct treatment for preventing HIV after exposure.

7. What are five ways to prevent HIV?
8. Condom use – Using condoms correctly reduces transmission risk.
9. PrEP (Pre-Exposure Prophylaxis) – Taking PrEP before exposure prevents HIV.
10. Regular testing – Early detection helps prevent further spread.
11. Education and awareness – Understanding transmission risks empowers prevention efforts.
12. Avoiding risky behaviors – Practicing safer sex and avoiding needle-sharing reduces exposure risks.

HIV in Women

Can Women Get HIV?

Yes, women can contract HIV, and in some regions, they are more affected than men. Young women and adolescent girls are especially vulnerable.

HIV in Women: Global Statistics

– Women account for 53% of HIV cases worldwide.

– In Sub-Saharan Africa, 63% of new HIV cases are among women.

– In the United States, Black women make up 58% of HIV cases among females, despite being only 13% of the female population.

Factors Affecting HIV Risk in Women

– Age: Young women aged 15-24 face the highest risk.

– Race: Women of color, particularly Black and Latina women, are disproportionately affected.

– Economic status: Lower-income women often lack access to HIV prevention and healthcare.

Gender-Specific Challenges in HIV Prevention

– Women often have limited decision-making power in sexual relationships.

– Societal stigma and gender-based violence increase vulnerability.

– Pregnancy and breastfeeding introduce additional risks for mother-to-child transmission.

Conclusion

Understanding HIV prevention, risk factors, and treatment options is essential for reducing transmission and improving health outcomes.

– PrEP and PEP provide medical protection for HIV-negative individuals.

– ART and U=U ensure that HIV-positive individuals live healthy lives without transmitting the virus.

– Routine HIV and STI testing are crucial for early detection and prevention.

HIV prevention is a shared responsibility, and by using the available tools, we can work towards an HIV-free future.

HIV Transmission and Women’s Health 

HIV Transmission in Women 

According to the U.S. National Institutes of Health (NIH), women are most likely to acquire HIV through condomless vaginal or anal sex with a male partner who has untreated HIV. Biological factors increase this risk: 

– The vaginal surface area is larger than the penile surface area, leading to greater exposure to HIV. 

– Semen remains in the vagina for several days, increasing potential transmission time. 

– Conditions such as vaginal yeast infections, bacterial vaginosis, or untreated STIs heighten susceptibility to HIV. 

– Age-related vaginal dryness can cause small tears, making transmission more likely. 

While female-to-female HIV transmission is rare, it can occur through: 

– Oral sex when there are cuts, sores, or bleeding gums. 

– Menstrual blood exposure. 

– Sharing sex toys without proper cleaning or protection. 

Other Ways HIV Can Be Transmitted 

HIV can also be passed through: 

– Sharing needles (drug use, tattooing, or medical settings with unsterilized equipment). 

– Receiving contaminated blood transfusions. 

– Breastfeeding from an HIV-positive mother. 

– Engaging in chemsex (drug use combined with sex, increasing risky behavior). 

– Occupational exposure, especially among sex workers, who are 10 times more likely to contract HIV. 

Health Concerns for Women Living with HIV 

Women face unique health challenges related to HIV, including: 

– Gynecological issues, such as increased risk of yeast infections and bacterial vaginosis. 

– Higher likelihood of cervical cancer, often linked to HPV co-infection. 

– Increased risk of heart disease due to chronic inflammation caused by HIV. 

– HIV medication side effects, which may interact with hormonal contraceptives and menopause treatments. 

– Menopausal symptoms, which may be more severe for women living with HIV, such as hot flashes, mood swings, and sexual dysfunction. 

Despite these concerns, women are underrepresented in HIV clinical trials, creating gaps in scientific knowledge about how HIV affects them differently from men. 

HIV and Fertility in Women 

Women living with HIV may experience fertility challenges, as the virus affects the reproductive system. Assisted reproductive technologies (ART), such as IVF, can help reduce the risk of transmission when trying to conceive. 

However, access to fertility treatments varies globally: 

– Finland & Norway do not offer fertility assistance to HIV-positive couples. 

– Germany limits assistance to HIV-positive men only. 

– The UK now allows HIV-positive couples to access IVF. 

These disparities highlight gender discrimination in reproductive healthcare for women living with HIV. 

Pregnancy and HIV 

Pregnancy poses additional risks for women with HIV: 

– HIV-positive women experience higher rates of pregnancy loss and ectopic pregnancies. 

– Mother-to-child transmission accounts for 90% of pediatric HIV cases globally. 

– In countries without access to ART, 15-40% of HIV-positive mothers pass the virus to their baby during pregnancy, childbirth, or breastfeeding. 

– Antiretroviral treatment (ART) during pregnancy reduces transmission risk by two-thirds. 

In low-income countries, limited access to formula milk forces some women to breastfeed despite the risk of transmission. 

HIV Treatment for Women 

While HIV treatments are the same for men and women, specific considerations apply to pregnant and breastfeeding women: 

– Tailored ART regimens may be recommended. 

– Drug interactions should be carefully monitored, especially with hormonal contraceptives. 

Access to prenatal and reproductive health services remains limited in some countries, where women require spousal consent to access healthcare. Global initiatives have improved prevention and treatment efforts: 

– In 2022, 210,000 adolescent girls and young women (15-24 years old) acquired HIV—a 50% decrease from 2010. 

– Mother-to-child transmission prevention programs have averted 3.4 million HIV infections in children since 2000. 

Transgender Women and HIV 

Transgender women face higher HIV risks due to: 

– Stigma and discrimination limiting access to healthcare. 

– Lack of gender-affirming care alongside HIV treatment. 

– Hormone therapy interactions with HIV medications, requiring careful monitoring. 

HIV Prevention: PrEP and PEP for Women 

– PrEP (Pre-Exposure Prophylaxis): Prevents HIV when taken before exposure. 

– PEP (Post-Exposure Prophylaxis): Emergency medication taken within 72 hours after potential HIV exposure. 

Access Gaps in PrEP and PEP for Women 

– Only 42% of high-risk regions in sub-Saharan Africa offer HIV prevention programs for adolescent girls. 

– Low awareness of PrEP among women limits uptake. 

– Stigma and discrimination prevent many women from seeking prevention options. 

– Transgender women of color face additional barriers due to medical mistrust. 

Closing these gaps can significantly reduce HIV acquisition rates among women. 

HIV Stigma and Women 

Women living with HIV, especially those in key populations (e.g., transgender women and sex workers), face violence, discrimination, and stigma. 

– Gender-based violence increases vulnerability to HIV. 

– Legal restrictions prevent women in some countries from making sexual and reproductive health choices. 

– Mandatory HIV testing for marriage exists in some regions. 

– Transgender women face criminalization in multiple countries. 

Efforts to combat stigma include: 

– Human rights advocacy to change discriminatory laws. 

– Community involvement in the HIV response. 

– Education campaigns to reduce misinformation and promote gender equality in healthcare. 

Living a Healthy Life with HIV 

Due to advances in HIV treatment, women can lead long, healthy lives. The Undetectable = Untransmittable (U=U) concept empowers HIV-positive women in relationships by eliminating transmission risks. 

The Future of HIV Care 

Ending the HIV epidemic requires continuous efforts: 

– Expanding access to PrEP and PEP for women. 

– Improving gender-specific research in HIV treatment. 

– Challenging social and legal barriers that prevent women from accessing care. 

– Investing in healthcare equity to close the HIV gender gap. 

At ViiV Healthcare, they are committed to empowering women and transgender individuals in their fight against HIV. 

References

1. Body Fluids That Transmit HIV. CDC. Published 2023. Accessed November 7, 2023. https://www.cdc.gov/hiv/causes/

2. HIV Transmission. CDC. Published 2023. Accessed November 7, 2023.

3. Ways HIV Can Be Transmitted. CDC. Published 2023. Accessed November 7, 2023. https://www.cdc.gov/hiv/causes/

4. Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk. AIDS. 2014;28(10):1509-1519. doi:https://doi.org/10.1097/qad.0000000000000298

5. HIV Treatment as Prevention. CDC. Published 2023. Accessed November 7, 2023. https://www.cdc.gov/hiv/risk/art/index.html

6. Detailed STD Facts – HIV/AIDS & STDs. CDC. Published 2023. Accessed November 7, 2023. https://www.cdc.gov/healthyyouth/about/hivstd_prevention.htm

7. Condom Fact Sheet In Brief. CDC. Published 2023. Accessed November 7, 2023. https://www.cdc.gov/hiv/prevention/condoms.html

8. Hayes R, Watson-Jones D, Celum C, van, Wasserheit JN. Treatment of sexually transmitted infections for HIV prevention: end of the road or new beginning? AIDS. 2010;24(Suppl 4):S15-S26. doi:https://doi.org/10.1097/01.aids.0000390704.35642.47

9. UNAIDS Point of View the Female Condom and AIDS UNAIDS Best Practice Collection; 1997. https://www.unaids.org/sites/default/files/media_asset/fcondompv_en_1.pdf

10. Pre-Exposure Prophylaxis. HIV.gov. Published 2022. Accessed November 8, 2023. https://www.hiv.gov/hiv-basics/hiv-prevention/using-hiv-medication-to-reduce-risk/pre-exposure-prophylaxis/

11. HIV Prevention. Test.HIV.Published 2015. Accessed November 8, 2023.

12. Deciding to Take PrEP. Published 2023. Accessed November 10, 2023. https://www.cdc.gov/stophivtogether/hiv-prevention/pep.html

13. What Is Injectable HIV PrEP? CLINICIANS’ QUICK GUIDE TM. https://www.cdc.gov/stophivtogether/library/topics/prevention/brochures/cdc-lsht-prevention-brochure-clinicians-quick-guide-what-is-injectable-hiv-prep.pdf

14. About PEP. Published 2023. Accessed November 10, 2023. https://www.cdc.gov/stophivtogether/hiv-prevention/pep.html

15. Preventing Perinatal Transmission of HIV | NIH. Nih.gov. Published 2023. Accessed November 10, 2023. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/preventing-perinatal-transmission-hiv

16. HIV Prevention.Test.HIV.Published 2015. Accessed November 10, 2023. https://www.test.hiv/preventing-hiv

17. Condom and Lubricant Programming in High HIV Prevalence Countries UNAIDS 2014 | GUIDANCE NOTE. https://www.unaids.org/sites/default/files/media_asset/condoms_guidancenote_en.pdf

18. Infographic—Progress Toward an HIV Vaccine. Nih.gov. Published May 17, 2018. Accessed November 9, 2023. https://www.niaid.nih.gov/diseases-conditions/infographic-hiv-vaccine

19. Experimental HIV vaccine regimen safe but ineffective, study finds. National Institutes of Health (NIH). Published January 18, 2023. Accessed November 9, 2023. https://www.nih.gov/news-events/news-releases/experimental-hiv-vaccine-regimen-safe-ineffective-study-finds

20. Laher F, Bekker LG, Garrett N, Lazarus EM, Gray GE. Review of preventative HIV vaccine clinical trials in South Africa. Archives of Virology. 2020;165(11):2439-2452. doi:https://doi.org/10.1007/s00705-020-04777-2

21. Prodger JL, Kaul R. The biology of how circumcision reduces HIV susceptibility: broader implications for the prevention field. Aids Research and Therapy. 2017;14(1). doi:https://doi.org/10.1186/s12981-017-0167-6

22. Yuan T, Fitzpatrick T, Nai Ying Ko, et al. Circumcision to prevent HIV and other sexually transmitted infections in men who have sex with men: a systematic review and meta-analysis of global data. The Lancet Global Health. 2019;7(4):e436-e447. doi:https://doi.org/10.1016/s2214-109x(18)30567-9

23. What’s the difference between PrEP and PEP for HIV prevention? aidsmap.com. Published January 13, 2022. Accessed November 9, 2023. https://www.aidsmap.com/about-hiv/faq/whats-difference-between-prep-and-pep-hiv-prevention

24. Using antibiotics to prevent STIs. aidsmap.com. Published May 26, 2023. Accessed November 16, 2023. https://www.aidsmap.com/about-hiv/using-antibiotics-prevent-stis

25. Marfatia YS, Pandya I, Mehta K. Condoms: Past, present, and future. Indian journal of sexually transmitted diseases and AIDS. 2015;36(2):133-139. doi:https://doi.org/10.4103/0253-7184.167135

26. Dangerous inequalities: World AIDS Day report 2022. Geneva: Joint United Nations Programme on HIV/AIDS; 2022. Licence: CC BY-NC-SA 3.0 IGO.

27. HIV and AIDS Epidemic Global Statistics. HIV.gov. Published 2022. Accessed September 28, 2023. https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics/

28. 2022 GLOBAL HIV STATISTICS.; 2022. Accessed September 28, 2023. https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf

29. Mårdh O, Quinten C, Giorgi Kuchukhidze, et al. HIV among women in the WHO European Region – epidemiological trends and predictors of late diagnosis, 2009-2018. Eurosurveillance. 2019;24(48). doi:https://doi.org/10.2807/1560-7917.es.2019.24.48.1900696

30. HIV Diagnoses. Centres for Disease Control and Prevention. Published August 18, 2022. Accessed September 28, 2023. https://www.cdc.gov/hiv/data-research/facts-stats/women.html

31. Poteat T, Ackerman B, Diouf D, et al. HIV prevalence and behavioural and psychosocial factors among transgender women and cisgender men who have sex with men in 8 African countries: A cross-sectional analysis. PLOS Medicine. 2017;14(11):e1002422-e1002422. doi:https://doi.org/10.1371/journal.pmed.1002422
32. Women and HIV: a spotlight on adolescent girls and young women.; 2019. https://www.unaids.org/sites/default/files/media_asset/2019_women-and-hiv_en.pdf

33. Chaturaka Rodrigo, Senaka Rajapakse, HIV, poverty and women, International Health, Volume 2, Issue 1, March 2010, Pages 9–16, https://doi.org/10.1016/j.inhe.2009.12.003

34. American Psychological Association. HIV/AIDS and Socioeconomic Status. https://www.apa.org. Published 2010. Accessed September 28, 2023. https://www.apa.org/pi/ses/resources/publications/hiv-aids

35. HIV and Women | NIH. Nih.gov. Published 2021. Accessed September 29, 2023. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-women

36. Canada’s source for HIV and hepatitis C information. Published July 4, 2022. Accessed September 29, 2023. https://www.catie.ca/prevention-in-focus/hiv-and-the-female-genital-tract-what-does-it-mean-for-hiv-prevention

37. Office on Women’s Health. Women and HIV | Office on Women’s Health. Womenshealth.gov. Published 2013. Accessed September 29, 2023. https://www.womenshealth.gov/hiv-and-aids/women-and-hiv

38. HIV Transmission. Published 2023. Accessed September 29, 2023. https://www.cdc.gov/hiv/causes/

39. Prevention Gap Report; 2016. Accessed September 29, 2023. https://www.unaids.org/sites/default/files/media_asset/2016-prevention-gap-report_en.pdf

40. gov . How Does HIV Impact Women’s Health? HIV.gov. Published 2022. Accessed October 13, 2023.

41. Tariq S, Burns F, Gilson R, Sabin C. PRIME (Positive Transitions Through the Menopause) Study: a protocol for a mixed-methods study investigating the impact of the menopause on the health and well-being of women living with HIV in England. BMJ Open. 2019;9(6):e025497-e025497. doi:https://doi.org/10.1136/bmjopen-2018-025497

42. Mirjam Curno, Rossi S, Ioannis Hodges-Mameletzis, Johnston R, Price MA, Heidari S. A Systematic Review of the Inclusion (or Exclusion) of Women in HIV Research. Journal of Acquired Immune Deficiency Syndromes. 2016;71(2):181-188. doi:https://doi.org/10.1097/qai.0000000000000842

43. British HIV Association. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). Available at: https://www.bhiva.org/file/RVYKzFwyxpgiI/treatment-guidelines-2016-interim-update.pdf. Accessed September 2023

44. Kushnir VA, Lewis W. Human immunodeficiency virus/acquired immunodeficiency syndrome and infertility: emerging problems in the era of highly active antiretrovirals. Fertility and Sterility. 2011;96(3):546-553. doi:https://doi.org/10.1016/j.fertnstert.2011.05.094

45. Bell M, Edelstein M, Hurwitz S, Irwin R. Accessibility and availability of assisted reproductive technology for people living with HIV in Europe: a thematic literature review. Aids Care-psychological and Socio-medical Aspects of Aids/hiv. 2019;32(8):949-953. doi:https://doi.org/10.1080/09540121.2019.1707471

46. HIV in pregnancy: a review acknowledgements.; 1998. Accessed 2023. https://www.unaids.org/sites/default/files/media_asset/jc151-hiv-in-pregnancy_en_1.pdf

47. NIH | Nih.gov. HIV Medicines During Pregnancy and Childbirth. Published 2021. Accessed October 9, 2023. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-medicines-during-pregnancy-and-childbirth

48. Women and girls and HIV;2018. Accessed 2023. https://www.unaids.org/sites/default/files/media_asset/women_girls_hiv_en.pdf

49. The Path That Ends Aids 2023 Unaids Global Aids Update Executive Summary; 2023. Accessed October 9, 2023. https://www.unaids.org/sites/default/files/media_asset/2023-unaids-global-aids-update-summary_en.pdf

50. Van Gerwen OT, Blumenthal JS. Providing gender-affirming care to transgender and gender-diverse individuals with and at risk for HIV. Topics in antiviral medicine. 2023;31(1):3-13. Accessed October 9, 2023. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10089290/

51. Lakshmi Goparaju, Praschan N, Lari Warren-Jeanpiere, Experton LS, Young M, Kassaye S. Stigma, Partners, Providers and Costs: Potential Barriers to PrEP Uptake among US Women. Journal of AIDS and Clinical Research. 2017;08(09). doi:https://doi.org/10.4172/2155-6113.1000730
52. Baldwin A, Light B, Allison WE. Pre-Exposure Prophylaxis (PrEP) for HIV Infection in Cisgender and Transgender Women in the U.S.: A Narrative Review of the Literature. Archives of Sexual Behaviour. 2021;50(4):1713-1728. doi:10.1007/s10508-020-01903-8.

53. We’ve got the power – Women, adolescent girls and the HIV response; 2020. Accessed 2023. https://www.unaids.org/sites/default/files/media_asset/2020_women-adolescent-girls-and-hiv_en.pdf

54. Women and HIV: Invisible No Longer | Terrence Higgins Trust. Tht.org.uk. Published 2023. Accessed October 31, 2023. https://www.tht.org.uk/our-work/our-campaigns/past-campaigns/women-and-hiv-invisible-no-longer

55. PEP/PREP: Sexual Health South West London. Sexual Health South West London. Published 2023. Accessed October 31, 2023. https://shswl.nhs.uk/pepprep

56. Centers for Disease Control and Prevention (CDC), Diagnoses of HIV Infection in the United States and Dependent Areas, 2018: Women. Published May 7, 2020, Accessed November 21, 2023. https://www.cdc.gov/hiv/NP-GBL-HVX-COCO-230024 | December 2022

57. ViiV Healthcare. Positive Perspectives Study, Wave 2 Results Report. Available at: https://viivhealthcare.com/content/dam/cf-viiv/viivhealthcare/en_GB/files/211203-updated-pp2-report-v9.0.pdf. Last accessed: September 2024.NP-GBL-HVX-COCO-240046 February 2025

58. UNAIDS Global HIV & AIDS Statistics – 2020 Fact Sheet. Available from: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Last accessed: February 2021

59. HIV and AIDS Clinical Trials. (n.d.). Nih.Gov. Retrieved 10 October 2023, from https://hivinfo.nih.gov/understanding-hiv/fact-sheets/hiv-and-aids-clinical-trials

60. Office of the Commissioner. (2019, December 20). Understanding Investigational Drugs. U.S. Food and Drug Administration. https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-investigational-drugs

61. Kwan TH, Chan CP, Wong NS, Lee SS. Awareness of HIV functional cure and willingness in participating in related clinical trials: comparison between antiretroviral naïve and experienced men who have sex with men living with HIV. BMC Infectious Diseases. 2022 Apr 15;22(1):383. https://doi.org/10.1186/s12879-022-07346-x

62. Bailon L, Mothe B, Berman L, Brander C. Novel approaches towards a functional cure of HIV/AIDS. Drugs. 2020 Jun;80(9):859-68. doi: 1007/s40265-020-01322-y

63. Hussein M, Molina MA, Berkhout B, Herrera-Carrillo E. A CRISPR-Cas Cure for HIV/AIDS. International Journal of Molecular Sciences. 2023 Jan 13;24(2):1563. doi: 3390/ijms24021563

64. Our Approach to an HIV Cure. (2018, March 28). American Gene Technologies. https://www.americangene.com/pipeline/hiv-aids/

65. Pre-exposure Prophylaxis (PrEP) to Reduce HIV Risk. (n.d.). Nih.Gov; National Institute of Allergy and Infectious Diseases. Retrieved 10 October 2023, from https://www.niaid.nih.gov/diseases-conditions/pre-exposure-prophylaxis-prep

66. Experimental HIV vaccine regimen safe but ineffective, study finds. (2023, January 18). National Institutes of Health (NIH). https://www.nih.gov/news-events/news-releases/experimental-hiv-vaccine-regimen-safe-ineffective-study-finds

67. Nixon CC, Mavigner M, Sampey GC, Brooks AD, Spagnuolo RA, Irlbeck DM, Mattingly C, Ho PT, Schoof N, Cammon CG, Tharp GK. Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo. Nature. 2020 Feb 6;578(7793):160-5. doi:1038/s41586-020-1951-3

68. Clinical Research Regulation For United Kingdom | ClinRegs. Nih.gov. Published 2023. Accessed October 11, 2023. https://clinregs.niaid.nih.gov/country/united-kingdom

69. Phases of clinical trials. Cancer Research UK. Published October 21, 2014. Accessed October 11, 2023. https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/what-clinical-trials-are/phases-of-clinical-trials

70. Phases of clinical trials. American Kidney Fund. Published November 2, 2021. Accessed October 18, 2023. https://www.kidneyfund.org/treatments/clinical-trials/phases-clinical-trials

71. Diversity and Inclusion in Clinical Trials. NIMHD. Published 2021. Accessed October 12, 2023. https://www.nimhd.nih.gov/resources/understanding-health-disparities/diversity-and-inclusion-in-clinical-trials.html

72. National Academies of Sciences, Engineering, and Medicine; Policy and Global Affairs; Committee on Women in Science, Engineering, and Medicine; Committee on Improving the Representation of Women and Underrepresented Minorities in Clinical Trials and Research; Bibbins-Domingo K, Helman A, editors. Improving Representation in Clinical Trials and Research: Building Research Equity for Women and Underrepresented Groups. Washington (DC): National Academies Press (US); 2022 May 17. 2, Why Diverse Representation in Clinical Research Matters and the Current State of Representation within the Clinical Research Ecosystem. Available from: https://www.ncbi.nlm.nih.gov/books/NBK584396/

73. Schwartz AD, Alsan M, Morris AA, Halpern SD. Why Diverse Clinical Trial Participation Matters. The New England Journal of Medicine. 2023;388(14):1252-1254. doi:https://doi.org/10.1056/nejmp2215609

74. Gross AS, Harry A, Clifton CS, Oscar Della Pasqua. Clinical trial diversity: An opportunity for improved insight into the determinants of variability in drug response. British Journal of Clinical Pharmacology. 2022;88(6):2700-2717. doi:https://doi.org/10.1111/bcp.15242

75. Waters L, Ahmed C, Angus B, et al. BHIVA Guidelines for the Treatment of HIV-1-Positive Adults with Antiretroviral Therapy 2015 (2016 Interim Update) Writing Group.; 2016. https://www.bhiva.org/file/RVYKzFwyxpgiI/treatment-guidelines-2016-interim-update.pdf

76. The pros and cons of taking part in a clinical trial. Cancer Research UK. Published October 21, 2014. Accessed October 17, 2023. https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/what-you-should-be-told-about-a-clinical-trial/advantages-and-drawbacks

77. Tarimo EA, Ambikile J, Munseri P, Bakari M. Perception of potential harm and benefits of HIV vaccine trial participation: A qualitative study from urban Tanzania. PLoS One. 2019 Nov 8;14(11):e0224831. https://doi.org/10.1371/journal.pone.0224831

78. Benefits, Risks, and Safety Measures. NHLBI, NIH. Published March 24, 2022. Accessed October 17, 2023. https://www.nhlbi.nih.gov/research/clinical-trials/safety-benefits-risks

HIV Cure: Advancing Towards the End of the HIV Epidemic

The biggest obstacle to permanently curing HIV is the virus’s ability to hide within the body by remaining dormant in immune cells, particularly CD4+ T-cells. These hidden viral reservoirs make complete eradication extremely challenging. 

Is There a Cure for HIV/AIDS?

Since the onset of the HIV/AIDS epidemic, researchers, scientists, and healthcare professionals have continuously worked to understand the virus and develop effective treatments. The advancements in antiretroviral therapy (ART) now allow people living with HIV to achieve undetectable viral loads, improving their health outcomes and preventing transmission to others (U=U: Undetectable = Untransmittable). 

Despite significant progress over the last four decades, the search for a definitive HIV cure remains a priority. While ART has transformed HIV into a manageable chronic condition, lifelong medication is still necessary. Treatment adherence is crucial since missing doses can lead to drug resistance, making HIV harder to control. Additionally, ART can sometimes cause side effects, affecting overall well-being. 

Even when undergoing antiretroviral treatment, people living with HIV often experience chronic inflammation and heightened immune system activity, which may increase their risk of cardiovascular disease, neurological disorders, and cancer. The social stigma surrounding HIV further reinforces the need for a long-term functional or sterilizing cure. 

Challenges in Finding a Cure for HIV

The greatest hurdle in eradicating HIV is its ability to enter a latent state within immune cells, particularly CD4+ T-cells. These latent reservoirs harbor the virus in a dormant form, making it invisible to the immune system and resistant to standard ART. If treatment is discontinued, HIV can reactivate, leading to viral rebound. 

Current HIV treatments prevent new infections within the body but do not eliminate infected cells with integrated viral DNA. This is why HIV remains persistent even when viral load becomes undetectable. Scientists are exploring strategies to reactivate hidden HIV and eliminate it, but overcoming this challenge requires groundbreaking research. 

At ViiV Healthcare, we are committed to tackling these complexities and driving HIV cure research forward. While eliminating latent HIV reservoirs remains a challenge, we continue to explore innovative solutions that bring us closer to a functional cure. 

New Strategies for Curing HIV 

The “Induce and Reduce” Approach

To develop an effective HIV cure, researchers are investigating multiple strategies. The ultimate goal is a sterilizing cure, where HIV is completely eliminated from the body. However, a more immediate and realistic goal is achieving a functional cure, where the virus remains under control without continuous ART. 

One of the most promising research directions is the “Induce and Reduce” strategy: 

– **Induce:** Activate latent HIV hidden in immune cells, making it detectable. 

– **Reduce:** Once the virus is exposed, eliminate infected cells through targeted therapies. 

This approach aims to flush out dormant HIV while continuing ART to prevent further spread. If successful, this method could pave the way toward long-term viral remission. 

Breakthrough Research in HIV Cure

One promising advancement in HIV cure research involves inhibitors of apoptosis (IAP), which reactivate latent HIV and make it vulnerable to elimination. Recent studies have demonstrated that IAP inhibitors activate immune pathways, exposing hidden HIV in animal models. Published in Nature, this research represents a major step toward a cure. 

Collaborations in HIV Cure Research

At ViiV Healthcare, they collaborate with leading scientists, biotech firms, government agencies, and academic institutions to accelerate HIV cure development. Our partnerships focus on: 

– Targeting HIV reservoirs through new gene-editing and immune-based therapies. 

– Developing innovative treatment approaches, such as latency-reversing agents. 

– Exploring long-acting therapies to improve patient outcomes. 

Notably, our work on the “Induce and Reduce” strategy was recognized among the Top 10 Most Significant Scientific Discoveries in 2020 by Nature. 

How Close Are We to a Cure for HIV?

The journey toward an HIV cure involves groundbreaking clinical trials and research efforts worldwide. Here are some key developments: 

– **February 2022:** A woman undergoing a stem cell transplant for leukemia achieved long-term HIV remission after stopping ART. 

– **July 2023:** The “Geneva Patient” became the latest individual potentially cured of HIV following a stem cell transplant from a donor with HIV-resistant mutations. 

– **July 2023:** The FDA fast-tracked EBT-101, a gene-editing therapy designed to remove HIV from infected cells. Clinical trials are currently underway. 

While these cases represent exciting progress, the treatments involved are not yet scalable to all 39 million people living with HIV globally. However, they provide valuable insights into potential cure strategies. 

The Future of HIV Cure Research

Developing an HIV cure requires a long-term commitment. At ViiV Healthcare, they focus on translating laboratory research into clinical applications. Our mission is to cure HIV, eliminate the treatment burden, and remove the stigma associated with the virus. 

If you or someone you know is living with HIV, consider participating in HIV cure clinical trials, contributing to the future of HIV research. 

Conclusion: Ending the HIV Epidemic

Achieving an HIV cure will transform millions of lives, ending the need for lifelong treatment and reducing the global impact of HIV/AIDS. While challenges remain, ongoing research, innovation, and collaboration between scientists and healthcare organizations bring us closer to this goal. 

At ViiV Healthcare, they remain committed to ending the HIV epidemic. We will be here until HIV is no longer a global health threat. 

References

1. S. Bertagnolio, Perno CF, Vella S, Pillay D. The Impact of HIV Drug Resistance on the Selection of First- and Second-Line ART in Resource-Limited Settings. The Journal of Infectious Diseases. 2013;207(suppl 2)
2. Poor CD4 Cell Recovery and Persistent Inflammation Despite Viral Suppression | NIH. HIV.gov. Published June 3, 2021. Accessed June 6, 2024. https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/poor-cd4-cell-recovery-and-persistent
3. Hileman CO, Funderburg NT. Inflammation, Immune Activation, and Antiretroviral Therapy in HIV. Current HIV/AIDS Reports. 2017;14(3):93-100. doi: https://doi.org/10.1007/s11904-017-0356-x
4. Bonney EY, Lamptey H, Kyei GB. HIV cure: an acceptability scientific agenda. Curr Opin HIV AIDS. 2023;18(1):12-17. doi:10.1097/COH.0000000000000771
5. HIV info. What is a latent HIV reservoir? Accessed January 2024 https://hivinfo.nih.gov/understanding-hiv/fact-sheets/what-latent-hiv-reservoir.
6. Castro-Gonzalez S, Colomer-Lluch M, Serra-Moreno R. Barriers for HIV Cure: The Latent Reservoir. AIDS Res Hum Retroviruses. 2018;34(9):739-759. doi:10.1089/AID.2018.0118.
7. Xu W, Li H, Wang Q, et al. Advancements in Developing Strategies for Sterilizing and Functional HIV Cures. Biomed Res Int. 2017;2017:6096134. doi:10.1155/2017/6096134
8. Nixon CC, Mavigner M, Sampey GC, et al. Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo. Nature. 2020;578(7793):160-165. doi:10.1038/s41586-020-1951-3
9. Viruses, microscopy and fast radio bursts: 10 remarkable discoveries from 2020. Nature. 2020;588(7839):596-598. doi: https://doi.org/10.1038/d41586-020-03514-8
10. Hsu J, Van Besien K, Glesby MJ, et al. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell. 2023;186(6):1115-1126.e8. doi:10.1016/j.cell.2023.02.030
11. No Rebound 20 Months After ART Stops After Novel Stem Cell Transplant. IAS conference on HIV Science. IAS 2023, July 23-26, 2023. Brisbane. Accessed January 2024. https://www.natap.org/2023/IAS/IAS_38.htm.
12. Excision BioTherapeutics Receives FDA Fast Track Designationfor EBT-101, a First-in-Class CRISPR-Based Gene Therapy Candidate to Functionally Cure HIV-1. Excision BioTherapeutics. July 20, 2023. Accessed January 2024. https://www.globenewswire.com/news-release/2023/07/20/2708048/0/en/Excision-BioTherapeutics-Receives-FDA-Fast-Track-Designation-for-EBT-101-a-First-in-Class-CRISPR-Based-Gene-Therapy-Candidate-to-Functionally-Cure-HIV-1.html.
13. HIV and AIDS Epidemic Global Statistics. HIV.gov. Published 2022. Accessed June 5, 2024. https://www.hiv.gov/hiv-basics/overview/data-and-trends/global-statistics